Genentech Halts Enrollment In Avastin Early-Stage Colon Cancer Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
The firm reports a higher rate of non-colon cancer related deaths in the AVANT trial for adjuvant use of bevacizumab.
You may also be interested in...
Avastin Trial Enrollment To Resume With Heightened Cardiac Monitoring
Roche/Genentech's AVANT study of bevacizumab showed no increase in cardiac adverse events, according to an independent data safety monitoring board.
Avastin Trial Enrollment To Resume With Heightened Cardiac Monitoring
Roche/Genentech's AVANT study of bevacizumab showed no increase in cardiac adverse events, according to an independent data safety monitoring board.
Genentech Files Avastin sBLA For Relapsed Metastatic Colorectal Cancer
The application would expand on an October labeling change which added third-line data.